Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit - Rowe, I. A.; Houlihan, D. D.; Mutimer, D. J. (Alimentary pharmacology & therapeutics, 2012)
Keywords: alpha -Interferon; Antiviral Agents - therapeutic use; Biological and medical sciences; Cohort Studies; Digestive system; Drug Therapy, Combination; Fibrosis; Follow-Up Studies; Gastroenterology. Liver. Pancreas. Abdomen; Genotypes; Hepacivirus - genetics; Hepatitis C; Hepatitis C virus; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - mortality; Human viral diseases; Humans; Infection; Infectious diseases; Interferon; Interferon alpha-2; Interferon-alpha - adverse effects; Interferon-alpha - therapeutic use; Lead; Liver - drug effects; Medical sciences; Models, Theoretical; Mortality; Oligopeptides - adverse effects; Oligopeptides - therapeutic use; Pharmacology. Drug treatments; Polyethylene Glycols - adverse effects; Polyethylene Glycols - therapeutic use; Proteinase inhibitors; Recombinant Proteins - adverse effects; Recombinant Proteins - therapeutic use; Ribavirin; Ribavirin - adverse effects; Ribavirin - therapeutic use; Risk groups; RNA, Viral - blood; Serine Proteinase Inhibitors - adverse effects; Serine Proteinase Inhibitors - therapeutic use; Time Factors; Treatment Outcome; Viral diseases; Viral hepatitis; Infection; Treatment; Viral disease; Cytokine; Digestive diseases; Hepatic disease; Advanced stage; Interferon; Models; Predictive factor; Protease inhibitor; Viral hepatitis C